An Australian Senate committee wrapped up its inquiry on barriers to regulated medical cannabis and published its final report this week.
Any improvements to regulatory overlap and availability pathways to locally produced products could brighten business prospects for entrepreneurs.
The committee’s final report came with 20 recommendations, covering a range of areas. including:
- More education for doctors on the endocannabinoid system and patients on the regulatory framework.
- A regulatory amendment allowing for the approval of multiple medicinal cannabis products in a single application.
- Recommendations on pricing, including the establishment of a compassionate access subsidy in consultation with industry.